HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effect of amphotericin B and micafungin combination on survival, histopathology, and fungal burden in experimental aspergillosis in the p47phox-/- mouse model of chronic granulomatous disease.

Abstract
Chronic granulomatous disease (CGD) is an inherited disorder of the NADPH oxidase characterized by recurrent life-threatening bacterial and fungal infections. We characterized the effects of single and combination antifungal therapy on survival, histopathology, and laboratory markers of fungal burden in experimental aspergillosis in the p47phox-/- knockout mouse model of CGD. CGD mice were highly susceptible to intratracheal Aspergillus fumigatus challenge, whereas wild-type mice were resistant. CGD mice were challenged intratracheally with a lethal inoculum (1.25 x 10(4) CFU/mouse) of A. fumigatus and received one of the following regimens daily from day 0 to 4 after challenge (n = 19 to 20 per treatment group): (i) vehicle, (ii) amphotericin B (intraperitoneal; 1 mg/kg of body weight), (iii) micafungin (intravenous; 10 mg/kg), or (iv) amphotericin B plus micafungin. The rank order of therapeutic efficacy based on prolonged survival, from highest to lowest, was as follows: amphotericin B plus micafungin, amphotericin B alone, micafungin alone, and the vehicle. Lung histology showed pyogranulomatous lesions and invasive hyphae, but without hyphal angioinvasion or coagulative necrosis. Treatment with micafungin alone or combined with amphotericin B produced swelling of invasive hyphae that was not present in mice treated with the vehicle or amphotericin B alone. Assessment of lung fungal burden by quantitative PCR showed no significant difference between treatment groups. Serum galactomannan levels were at background despite documentation of invasive aspergillosis by histology. Our findings showed the superior efficacy of the amphotericin B and micafungin combination compared to either agent alone after A. fumigatus challenge and also demonstrated unique features of CGD mice as a model for experimental aspergillosis.
AuthorsCarly G Dennis, William R Greco, Yseult Brun, Richard Youn, Harry K Slocum, Ralph J Bernacki, Russell Lewis, Nathan Wiederhold, Steven M Holland, Ruta Petraitiene, Thomas J Walsh, Brahm H Segal
JournalAntimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 50 Issue 2 Pg. 422-7 (Feb 2006) ISSN: 0066-4804 [Print] United States
PMID16436692 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antifungal Agents
  • Echinocandins
  • Lipopeptides
  • Lipoproteins
  • Peptides, Cyclic
  • Phosphoproteins
  • Amphotericin B
  • NADPH Oxidases
  • neutrophil cytosolic factor 1
  • Micafungin
Topics
  • Amphotericin B (administration & dosage)
  • Animals
  • Antifungal Agents
  • Aspergillosis (drug therapy, microbiology, pathology)
  • Aspergillus fumigatus (isolation & purification)
  • Drug Therapy, Combination
  • Echinocandins
  • Granulomatous Disease, Chronic (complications)
  • Lipopeptides
  • Lipoproteins (administration & dosage)
  • Lung (microbiology, pathology)
  • Micafungin
  • Mice
  • NADPH Oxidases
  • Peptides, Cyclic (administration & dosage)
  • Phosphoproteins (deficiency)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: